Hos præmenopausale kvinder var forøgelsen i BMD fra baseline til 18 måneders endpoint signifikant større i FORSTEO- gruppen – i lænderygsøjlen (4, 2% versus - 1, 9%; p < 0, 001) og hoften (3, 8% versus 0, 9%; p=0, 005) – sammenlignet med alendronatgruppen.
In premenopausal women, the increase in BMD from baseline to 18 month endpoint was significantly greater in the FORSTEO group compared with the alendronate group at the lumbar spine (4.2% versus − 1.9%; p < 0.001) and total hip (3.8% versus 0.9%; p=0.005).